Navigation Links
Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial

more than 300 papers in peer-reviewed journals.

Dr. Low is Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital. He is also Medical Director, Ontario Public Health Laboratories, Ministry of Health and Long-Term Care. He is a Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and Department of Medicine. He is currently Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

Post Your Comments:
(Date:11/25/2009)..., BRIDGEWATER, N.J., Nov. 25 Th...174; (etravirine) tablets, a non-nucleoside revers...e only NNRTI specifically indicated for use in tre...ologic failure with HIV-1 strains resistant to an ...traditional approval is based on 48-week data from...
(Date:11/25/2009)..., RANCHOCORDOVA,Calif.,Nov.25/PRNewswire/--AMPACFi...rporation(Nasdaq: APFC )announcedtodaythatitreceiv...wardattheAnnualStatewideEnvironmentalSummit,sponso...ation(CMTA),theIndustrialEnvironmentalAssociation(...)heldinSanDiego.Thisisthemostprestigiousawardavail...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Repo...report is available in its catalogue: ,, Unite...sts to 2015 ,, http://www.reportlinker.com/p0...s-and-Forecasts-to-2015.html ,, United States ...15 ,, Summary ,, This report is an essenti...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Class Action Notice for Minnesota Light Cigarette Litigation From Lommen Abdo Cole King 26 Stageberg P A 53638 1Class Action Notice for Minnesota Light Cigarette Litigation From Lommen Abdo Cole King 26 Stageberg P A 53638 2Class Action Notice for Minnesota Light Cigarette Litigation From Lommen Abdo Cole King 26 Stageberg P A 53638 3Make Eye Exams Part of the Back to School Routine 53633 1Make Eye Exams Part of the Back to School Routine 53633 2Make Eye Exams Part of the Back to School Routine 53633 3Make Eye Exams Part of the Back to School Routine 53633 4Looking at language 53629 1Looking at language 53629 2
...x, LLC announced today that,its licensing collabor...LabCorp), has commercially launched a new gene met...ses the biological specificity of ,DNA,methylation... the gene,GST-Pi. Methylation is a modification of...eveloping the methylation markers in this tissue a...
...tically Significant Reductions in Selected ...to be published in 2008 Proceedings of the America...cology, SAN DIEGO, May 16 ADVENTRX Pharmaceutica...egistrational bioequivalence,clinical study, ANX-5...ion,in general disorders and administration site c...
Other Medicine Technology:ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5
(Date:11/27/2009)... manufacturers who use medical load cells at the h...ars by bringing in technology partner Flintec earl...-active medical manufacturers are calling in Flint... projects, ensuring that progress will not be cons...y outdated technology. , ...
(Date:11/26/2009)...thiomolybdate (TM) has been shown in studies to be...isease caused by an overload of copper, and certai...tle, however, is known about how the drug works at...western University researchers now has provided an...of TM bound to copper-loaded metallochaperones. Th...
(Date:11/26/2009)...riangle Dental (RTDental), a leading dental group ...d the expansion of its services to include LUMINEE...llan. , Durham, NC (PR...ounce that Dr. Doug Macmillan, an experienced LUM...advanced training seminar. RTDental’s abili...
(Date:11/25/2009)...v. 25 Onyx Pharmaceuti...he company will host two investor events in Decemb...09 - 9:00 a.m. CT/10:00 a.m. ET ,, Principal ...ounding carfilzomib in relapsed and/or refractory ... Society of Hematology (ASH) Annual Meeting and Ex...
(Date:11/25/2009)...PRNewswire-USNewswire/ -- The Black AIDS Institute...rmine executive leadership for 2010. ,, The new...rs with specialties in public policy, law, finance...ess entrepreneurship. The Board also comes from a ...heterosexual and gay Black men and women, some liv...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...website, http://www.shirleyboard.com, has been re...r Outstanding Achievement in Website Development b... of Excellence WebAward,Designation. ShirleyBOARD...e allows caregivers to centrally store important,i...
...ymour, Iowa, was handed the keys to the E85-powere...f the September 15th Iowa vs. Iowa State,football ...the Ride, Iowa",raffle. The Iowa Farm Bureau donat...r Choice program. The custom designed,motorcycle w...
...pregnancy accelerates progression to full-blown AI...apy. The study, published in the October 1st issue...ilable online, revealed that pregnancy may, in fac...S were told that becoming pregnant would be unwise...
... in the U.S. millions of blood donors see a critic...ain. Of the 14.4 million units of whole blood coll...he four million whole blood-derived platelet conce... no medical requirement or clear need to do so. To...
...asdaq: LMNX ) today announced that management wil...ce to be held September 24-27, 2007, in New,York C...hrop, president and chief,executive officer, and H...nd may be accessed at Luminex,Corporation,s websit...
...: HOLX ) today announced that Glenn Muir, Chief F...bal Life Sciences Conference being held,September ..., NY. Interested parties are invited to listen to...pany,s website at, http://www.hologic.com/investor...
Other Medicine News:Health News:Elder Caregiving Site ShirleyBOARD.com Wins WebAward for Outstanding Online Community 2Health News:Renewable Fuel Chopper Raffle Nets $113,000 for American Lung Association Clean Air Choice Program 2Health News:Pregnancy may slow -- not accelerate -- progression to AIDS 2Health News:Pregnancy may slow -- not accelerate -- progression to AIDS 3Health News:Critical blood shortages eased by new technology 2Health News:Critical blood shortages eased by new technology 3Health News:Luminex Corporation To Present at UBS Global Life Sciences Conference 2
...ure MB Grade PRODUCT SPECIFICATIONS Form: Granular... Point (1.5%): 36.0 1.5C Remelt Point (1.5...n or equal to 1,200 gm/cm 2 Gel Strength (1.5%...re: less than or equal to 7% Turbidity (1.5...
...traces: chloride (Cl) ≤ 3000 mg/kg sulfate (...; 500 mg/kg Cd ≤ 10 mg/kg Co ≤ 10 mg/k...4; 10 mg/kg K ≤ 500 mg/kg Mg ≤ 10 mg/k...804; 10 mg/kg Pb ≤ 10 mg/kg Zn ≤ 10 mg...
...e MP, a multipurpose agarose, has been developed f...ucleic acids and separation of high molecular weig...Agarose MP is a high gel strength agarose ( 1800 g...se of low concentrations of agarose in electrophor...
Agarose, high gel strength, Molecular Biology Grade
Medicine Products: